IDEAYA Biosciences - IDYA Net Sales Margin

Brandmark of ideayabio.com (IDYA)

IDEAYA Biosciences develops precision oncology drugs, mitigating risks through a broad portfolio and alliances with the IT sector. US-based laboratories are implementing genetics-based treatment methods. Net profit returns on sales demonstrate efficiency dynamics, where the -1149.60 indicator determines the parameter status. However, the absence of commercial products leads to negative cash flow and a reliance on investments.

ideayabio.com (IDYA) - Net Return on Sales from 07/04/2022 to 11/19/2026

IDEAYA Bio - analytical breakdowns and key metrics (IDYA)

- share price and consensus valuation forecast:
Summary company analytics:IDEAYA Corp - IDYA
Finished products of IDEAYA Biosciences Inc

This indicator is calculated as the ratio of net income to revenue, measuring the efficiency of converting each dollar of sales into final income after deducting all operating and financial expenses. For IDEAYA Biosciences (IDYA), a negative net profit margin reflects a stage of intensive capital burn on oncology clinical trials in the absence of full-scale commercial product realization.